Pfizer Outlines Five-Year Turnaround Bet as Patent Expirations Near

Overview

• Pfizer is bracing for major patent expirations on Ibrance, Eliquis and Vyndaqel in 2027 and 2028 that are expected to pressure revenue.
• Following the failure of its weight-loss candidate, the company agreed to acquire Metsera for roughly $4.9 billion up front, with potential additional earnouts.
• The Metsera deal is framed as a pipeline‑building move intended to help offset the approaching patent cliff.
• Pfizer reached an agreement to make capital investments in the United States to avoid tariffs and to work with the government to improve affordability of its drugs.
• The article contends a business recovery over the next five years is possible, though it cautions that the dividend’s long-term level may not be fully maintained.